Latest Drugs, Latest Approval in NK1 receptor antagonists

What are NK1 receptor antagonists?

Neurokinin-1 (NK1) receptor antagonists are used for prevention of acute and delayed nausea and vomiting. The NK1 receptor antagonist competitively binds to the NK1 receptor, which blocks the binding of substance P and prevents the emetic signal being transmitted. NK1 receptor antagonists can be used in conjunction with 5-HT3-receptor antagonists and corticosteroids to augment their antiemetic activity.

Name Updated
Aprepitant (Aprepitant (oral/injection) [ a-prep-i-tant ]) 15-Aug-2023
Fosaprepitant (Fosaprepitant [ fos-a-prep-i-tan-t ]) 14-Aug-2023
Rolapitant (Rolapitant (oral) [ roe-la-pi-tant ]) 12-Aug-2023
Varubi (Rolapitant (oral - tablets) [ roe-la-pi-tant ]) 05-Aug-2023
Emend for injection (Fosaprepitant [ fos-a-prep-i-tan-t ]) 13-Jul-2023
Emend (Aprepitant (oral/injection) [ a-prep-i-tant ]) 13-Jul-2023